Skip to main content
Robert Paine III

Robert Paine III, MD

Languages spoken: English

Clinical Locations

University Hospital

Pulmonary, Clinic 3
801-581-7806
  • Robert Paine III, M.D. is an experienced Pulmonary and Critical Care Medicine physician who has been board certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. He cares for outpatients with a wide variety of pulmonary problems and has particular interest in chronic obstructive pulmonary disease (COPD) and unexplained shortness of breath. He has a major interest in care of critically ill patients in the medical intensive care unit (MICU) and has an ongoing research program related to the causes and treatment of acute lung injury.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

    Patient Rating

    5.0 /5

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 02, 2022

    Not just very good. Exceptional

    September 10, 2022

    He is so friendly and helpful

    July 23, 2022

    Dr. Paine and his team are superior to any health care providers I've had in my life. I cannot imagine preferring anyone else

    June 03, 2022

    The doctor was thorough, which was extremely comforting!

    April 22, 2022

    Dr Paine was excellent. He listened very attentively about my history and concerns. He examined my last several test results thoroughly. And explained everything to me. When I told him I didn't want to do the further testing he recommended because it's so difficult getting around the U hospital, he suggested doing it at the Sugarhouse location. So great to have options! Thanks

    February 07, 2022

    Excellent job

    January 27, 2022

    Excellent Physician

    March 05, 2021

    Dr Paine has been very thorough investigating what might cause my problem and has discussed various things that might help. His empathy is very appreciated.

  • Robert Paine III, M.D. is an experienced Pulmonary and Critical Care Medicine physician who has been board certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. He cares for outpatients with a wide variety of pulmonary problems and has particular interest in chronic obstructive pulmonary disease (COPD) and unexplained shortness of breath. He has a major interest in care of critically ill patients in the medical intensive care unit (MICU) and has an ongoing research program related to the causes and treatment of acute lung injury.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Robert Paine III [u0568862] > Division List
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

    Education history

    Research Fellow Pulmonary Medicine - Boston University Research Fellow
    Pulmonary/Critical Care - Boston University Fellow
    Residency Internal Medicine - Yale New Haven Hospital Resident
    Internal Medicine - Yale New Haven Hospital Intern
    Professional Medical Medicine - Washington University M.D.
    Philosophy - Oxford University B.Phil.
    Undergraduate Philosophy - Amherst College B.A.

    Selected Publications

    Journal Article

    1. Paine R, Chasse R, Halstead ES, Nfonoyim J, Park DJ, Byun T, Patel B, Molina-Pallete G, Harris ES, Garner F, Simms L, Ahuja S, McManus JL, Roychowdhury DF (2022). Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm). Mil Med.
    2. Tejwani V, Woo H, Liu C, Tillery AK, Gassett AJ, Kanner RE, Hoffman EA, Martinez FJ, Woodruff PG, Barr RG, Fawzy A, Koehler K, Curtis JL, Freeman CM, Cooper CB, Comellas AP, Pirozzi C, Paine R, Tashkin D, Krishnan JA, Sack C, Putcha N, Paulin LM, Zusman M, Kaufman JD, Alexis NE, Hansel NN (2022). Black carbon content in airway macrophages is associated with increased severe exacerbations and worse COPD morbidity in SPIROMICS. Respir Res, 23(1), 310.
    3. Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R 3rd, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB (2022). Bronchodilator Responsiveness in Tobacco-Exposed Persons with or without COPD. Chest.
    4. LeMaster WB, Quibrera PM, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG, ONeal WK, Anderson WH, Alexis NE, Bowler RP, Barr RG, Kaner RJ, Dransfield MT, Paine R 3rd, Kim V, Curtis JL, Martinez FJ, Hastie AT, Barjaktarevic I (2022). Clinical implications of low absolute blood eosinophil count in the SPIROMICS COPD cohort. Chest.
    5. Buhr RG, Barjaktarevic IZ, Quibrera PM, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN, Krishnan JA, Martinez FJ, McKleroy W, Paine R 3rd, Rennard SI, Tashkin DP, Woodruff PG, Kanner RE, Cooper CB, SPIROMICS Investigators (2023). Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med, 206(5), 554-562.
    6. Kaur K, Mohammadpour R, Ghandehari H, Reilly CA, Paine R 3rd, Kelly KE (2022). Effect of combustion particle morphology on biological responses in a Co-culture of human lung and macrophage cells. Atmos Environ (1994), 284.
    7. Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, Barr RG, Comellas AP, Couper DJ, Cooper CB, Freeman CM, Han MK, Kaner RJ, Labaki W, Martinez FJ, Ortega VE, Peters SP, Paine R, Woodruff P, Curtis JL, Huffnagle GB, Stringer KA, Bowler RP, Esther CR Jr, Reisdorph N, Huang YJ, SPIROMICS Research Group (2022). Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 206(4), 427-439.
    8. Baugh A, Buhr RG, Quibrera P, Barjaktarevic I, Barr RG, Bowler R, Han MK, Kaufman JD, Koch AL, Krishnan J, Labaki W, Martinez FJ, Mkorombindo T, Namen A, Ortega V, Paine R, Peters SP, Schotland H, Sundar K, Zeidler MR, Hansel NN, Woodruff PG, Thakur N (2022). Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity. Sleep, 45(8).
    9. Zhang T, Day NJ, Gaffrey M, Weitz KK, Attah K, Mimche PN, Paine R 3rd, Qian WJ, Helms MN (2022). Regulation of hyperoxia-induced neonatal lung injury via post-translational cysteine redox modifications. Redox Biol, 55, 102405.
    10. Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, Barr RG, Bowler R, Comellas AP, Cooper CB, Couper D, Criner G, Curtis JL, Dransfield M, Ejike C, Han MK, Hoffman E, Krishnan J, Krishnan JA, Mannino D, Paine R 3rd, Parekh T, Peters S, Putcha N, Rennard S, Thakur N, Woodruff PG (2021). Reconsidering the Utility of Race-Specific Lung Function Prediction Equations. Am J Respir Crit Care Med, 205(7), 819-829.
    11. Belz DC, Woo H, Putcha N, Paulin LM, Koehler K, Fawzy A, Alexis NE, Barr RG, Comellas AP, Cooper CB, Couper D, Dransfield M, Gassett AJ, Han M, Hoffman EA, Kanner RE, Krishnan JA, Martinez FJ, Paine R 3rd, Peng RD, Peters S, Pirozzi CS, Woodruff PG, Kaufman JD, Hansel NN, SPIROMICS Investigators (2022). Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Sci Total Environ, 829, 154694.
    12. Kaur K, Mohammadpour R, Sturrock A, Ghandehari H, Reilly C, Paine R 3rd, Kelly KE (2022). Comparison of biological responses between submerged, pseudo-air-liquid interface, and air-liquid interface exposure of A549 and differentiated THP-1 co-cultures to combustion-derived particles. J Environ Sci Health A Tox Hazard Subst Environ Eng, 57(7), 540-551.
    13. Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R 3rd, Woodruff PG, Han MK, Martinez FJ, Barr RG, Wells JM, Ortega VE, Hoffman EA, Kim V, Drummond MB, Bowler RP, Curtis JL, Cooper CB, Tashkin DP, Barjaktarevic IZ (2021). Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort. Chest, 161, 949-959.
    14. Zou C, Li F, Choi J, Haghighi B, Choi S, Rajaraman PK, Comellas AP, Newell JD, Lee CH, Barr RG, Bleecker E, Cooper CB, Couper D, Han M, Hansel NN, Kanner RE, Kazerooni EA, Kleerup EC, Martinez FJ, ONeal W, Paine R 3rd, Rennard SI, Smith BM, Woodruff PG, Hoffman EA, Lin CL (2021). Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Int J Chron Obstruct Pulmon Dis, 16, 1477-1496.
    15. Burkes RM, Couper DJ, Barjaktarevic IZ, Cooper CB, Labaki WW, Han MK, Woodruff PG, Lazarus SC, Parekh TM, Paine R 3rd, Comellas AP, Bowler RP, Loehr LR, Putcha N, Wise RA, Brown TT, Drummond MB (2021). Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. Chronic Obstr Pulm Dis, 8(2), 277-291.
    16. Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, Wells JM, Couper DJ, Labaki WW, Curtis JL, Han MK, Paine R 3rd, Woodruff PG, Criner GJ, Hansel NN, Diaz I, Ballman KV, Nakahira K, Choi ME, Martinez FJ, Choi AMK, Cloonan SM (2021). Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. Respir Res, 22(1), 126.
    17. Dunican EM, Elicker BM, Henry T, Gierada DS, Schiebler ML, Anderson W, Barjaktarevic I, Barr RG, Bleecker ER, Boucher RC, Bowler R, Christenson SA, Comellas A, Cooper CB, Couper D, Criner GJ, Dransfield M, Doerschuk CM, Drummond MB, Hansel NN, Han MK, Hastie AT, Hoffman EA, Krishnan JA, Lazarus SC, Martinez FJ, McCulloch CE, ONeal WK, Ortega VE, Paine R 3rd, Peters S, Schroeder JD, Woodruff PG, Fahy JV (2022). Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. Am J Respir Crit Care Med, 203(8), 957-968.
    18. Al-Kindi SG, Brook RD, Bhatt U, Brauer M, Cushman WC, Hanson HA, Kostis J, Lash JP, Paine R 3rd, Raphael KL, Rapp S, Tamariz L, Wright JT Jr, Rajagopalan S, SPRINT Research Group (2021). The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure: A Post Hoc Analysis of SPRINT. Hypertension, 77(3), 813-822.
    19. Kaur K, Overacker D, Ghandehari H, Reilly C, Paine R 3rd, Kelly KE (2020). Determining real-time mass deposition with a quartz crystal microbalance in an electrostatic, parallel-flow, air-liquid interface exposure system. J Aerosol Sci, 151.
    20. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, Grissom CK, Buckel WR, Srivastava R, Butler AM, Groat D, Haaland B, Ying J, Harris E, Johnson S, Paine R 3rd, Greene T (2020). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. Ann Am Thorac Soc.
    21. Zusman M, Gassett AJ, Kirwa K, Barr RG, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Paine R, Paulin L, Pirozzi C, Rule A, Hansel NN, Kaufman JD (2020). "Modeling Residential Indoor Concentrations of PM2.5 , NO2 , NOx , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air Study". Indoor Air, 31(3), 702-716.
    22. Burkes RM, Ceppe AS, Couper DJ, Comellas AP, Wells JM, Peters SP, Criner GJ, Kanner RE, Paine R 3rd, Christenson SA, Cooper CB, Barjaktarevic IZ, Krishnan JA, Labaki WW, Han MK, Curtis JL, Hansel NN, Wise RA, Drummond MB, SPIROMICS collaborators (2020). Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstr Pulm Dis, 7(4), 370-381.
    23. Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, ONeal W, Hoffman EA, Couper D, Quibrera M, Criner G, Dransfield MT, Han MK, Hansel NN, Krishnan JA, Lazarus SC, Peters SP, Barr RG, Martinez FJ, Woodruff PG, SPIROMICS investigators (2020). Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort. Int J Chron Obstruct Pulmon Dis, 15, 1887-1898.
    24. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, Buckel WR, Srivastava R, Harris ES, Leither LM, Johnson SA, Paine R 3rd, Greene T (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Ann Am Thorac Soc, 17(8), 1008-1015.
    25. Zhang WZ, Oromendia C, Kikkers SA, Butler JJ, OBeirne S, Kim K, ONeal WK, Freeman CM, Christenson SA, Peters SP, Wells JM, Doerschuk C, Putcha N, Barjaktarevic I, Woodruff PG, Cooper CB, Bowler RP, Comellas AP, Criner GJ, Paine R 3rd, Hansel NN, Han MK, Crystal RG, Kaner RJ, Ballman KV, Curtis JL, Martinez FJ, Cloonan SM (2020). Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. Sci Rep, 10(1), 10562.
    26. Smith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, Bertoni A, Coxson HO, Cooper C, Couper DJ, Criner G, Dransfield MT, Han MK, Hansel NN, Jacobs DR Jr, Kaufman JD, Lin CL, Manichaikul A, Martinez FJ, Michos ED, Oelsner EC, Paine R 3rd, Watson KE, Benedetti A, Tan WC, Bourbeau J, Woodruff PG, Barr RG, MESA Lung CanCOLD and SPIROMICS Investigators (2020). Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA, 323(22), 2268-2280.
    27. Ortega VE, Li X, ONeal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, Barr RG, Cooper C, Couper D, Han MK, Kanner RE, Kleerup EC, Martinez FJ, Paine R 3rd, Peters SP, Pirozzi C, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER, NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study SPIROMICS (2021). The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS. Am J Respir Crit Care Med, 201(5), 540-554.
    28. Grant GJ, Liou TG, Paine R 3rd, Helms MN (2020). High-mobility group box-1 increases epithelial sodium channel activity and inflammation via the receptor for advanced glycation end products. Am J Physiol Cell Physiol, 318(3), C570-C580.
    29. Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, Wells JM, Hastie AT, Labaki WW, Cooper CB, Comellas AP, Criner GJ, Krishnan JA, Paine R 3rd, Hansel NN, Bowler RP, Barr RG, Peters SP, Woodruff PG, Curtis JL, Han MK, Ballman KV, Martinez FJ, Choi AM, Nakahira K, Cloonan SM, Choi ME, SPIROMICS Investigators (2020). Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight, 5(3).
    30. Paulin LM, Gassett AJ, Alexis NE, Kirwa K, Kanner RE, Peters S, Krishnan JA, Paine R 3rd, Dransfield M, Woodruff PG, Cooper CB, Barr RG, Comellas AP, Pirozzi CS, Han M, Hoffman EA, Martinez FJ, Woo H, Peng RD, Fawzy A, Putcha N, Breysse PN, Kaufman JD, Hansel NN, for SPIROMICS investigators (2019). Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. JAMA Intern Med, 180(1), 106-115.
    31. Bostwick AD, Jones BE, Paine R, Goetz MB, Samore M, Jones M (2019). Potential Impact of Hospital-acquired Pneumonia Guidelines on Empiric Antibiotics. An Evaluation of 113 Veterans Affairs Medical Centers. Ann Am Thorac Soc, 16(11), 1392-1398.
    32. Kaur K, Mohammadpour R, Jaramillo IC, Ghandehari H, Reilly C, Paine R, Kelly KE (2019). Application of a Quartz Crystal Microbalance to Measure the Mass Concentration of Combustion Particle Suspensions. J Aerosol Sci, 137.
    33. Arjomandi M, Zeng S, Barjaktarevic I, Barr RG, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB, Couper DJ, Curtis JL, Dransfield MT, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Paine R 3rd, Peters SP, Rennard SI, Woodruff PG, SPIROMICS Investigators (2019). Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. Eur Respir J, 54(4).
    34. Brown SM, Paine R 3rd, Lanspa M, Gong M (2019). Value beyond the P: The Case for Higher-Quality and Better-publicized Pilot and Feasibility Trials. Ann Am Thorac Soc, 16(10), 1230-1233.
    35. Middleton EA, Rowley JW, Campbell RA, Grissom CK, Brown SM, Beesley SJ, Schwertz H, Kosaka Y, Manne BK, Krauel K, Tolley ND, Eustes AS, Guo L, Paine R 3rd, Harris ES, Zimmerman GA, Weyrich AS, Rondina MT (2019). Sepsis alters the transcriptional and translational landscape of human and murine platelets. Blood, 134(12), 911-923.
    36. Oelsner EC, Ortega VE, Smith BM, Nguyen JN, Manichaikul AW, Hoffman EA, Guo X, Taylor KD, Woodruff PG, Couper DJ, Hansel NN, Martinez FJ, Paine R 3rd, Han MK, Cooper C, Dransfield MT, Criner G, Krishnan JA, Bowler R, Bleecker ER, Peters S, Rich SS, Meyers DA, Rotter JI, Barr RG (2019). A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. Am J Respir Crit Care Med, 200(6), 721-731.
    37. Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, Barr RG, Comellas AP, Hansel NN, Cooper CB, Barjaktarevic I, Kanner RE, Paine R 3rd, McDonald MN, Krishnan JA, Peters SP, Woodruff PG, ONeal WK, Diao W, He B, Martinez FJ, Standiford TJ, Stringer KA, Han MK (2019). Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. Sci Rep, 9(1), 11367.
    38. Brown SM, Paine R 3rd (2019). Asking Causal Questions of Observational Data: The Quest Continues. Ann Am Thorac Soc, 16(8), 977-979.
    39. Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD Jr, Lee CH, Barr RG, Bleecker E, Cooper CB, Couper D, Han ML, Hansel NN, Kanner RE, Kazerooni EA, Kleerup EAC, Martinez FJ, ONeal W, Paine R 3rd, Rennard SI, Smith BM, Woodruff PG, Lin CL (2019). Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respir Res, 20(1), 153.
    40. Kaur K, Jaramillo IC, Mohammadpour R, Sturrock A, Ghandehari H, Reilly C, Paine R 3rd, Kelly KE (2019). Effect of collection methods on combustion particle physicochemical properties and their biological response in a human macrophage-like cell line. J Environ Sci Health A Tox Hazard Subst Environ Eng, 54(12), 1170-1185.

    Letter

    1. Baron RM, Christman JW, Liu KD, Matthay MA, Self WH, McVerry BJ, Hite RD, Paine R 3rd, Wurfel MM, Shapiro NI, Adams PW, Schmidt EP, Ringwood N (2021). Monitoring Research Blood Sampling in Critically Ill Patients: Avoiding Iatrogenic Anemia. [Letter to the editor]. Am J Respir Crit Care Med, 202(6), 885-887.

    Other

    1. OToole J, Woo H, Putcha N, Cooper CB, Woodruff P, Kanner RE, Paine R, Bowler RP, Comellas A, Hoth KF, Krishnan JA, Han M, Dransfield M, Iyer AS, Couper D, Peters SP, Criner G, Kim V, Barr RG, Martinez FJ, Hansel NN, Eakin MN, SPIROMICS Investigators (2023). Comparative Impact of Depressive Symptoms and FEV1% on Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc (19(2), pp. 171-178). United States.
    2. Oh AL, Mularski RA, Barjaktarevic I, Barr RG, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Paine R 3rd, Parekh TM, Peters SP, Christenson SA, Woodruff PG, SPIROMICS Smoking Resilience Group (2022). Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS. Ann Am Thorac Soc (18(11), pp. 1822-1831). United States.
    3. Radicioni G, Ceppe A, Ford AA, Alexis NE, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez FJ, Ozkan E, Paine R 3rd, Woodruff PG, ONeal WK, Boucher RC, Kesimer M (2021). Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med (9(11), pp. 1241-1254). England.
    4. Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R 3rd, Ronish B, Kanner RE, Dransfield M, Hoesterey D, Buhr RG, Barr RG, Dolezal B, Ortega VE, Drummond MB, Arjomandi M, Kaner RJ, Kim V, Curtis JL, Bowler RP, Martinez F, Labaki WW, Cooper CB, ONeal WK, Criner G, Hansel NN, Krishnan JA, Woodruff P, Couper D, Tashkin D, Barjaktarevic I (2021). Ratio of FEV1/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. Chest (160(1), pp. 94-103). United States.
    5. Grant GJ, Mimche PN, Paine R 3rd, Liou TG, Qian WJ, Helms MN (2021). Enhanced epithelial sodium channel activity in neonatal Scnn1b mouse lung attenuates high oxygen-induced lung injury. Am J Physiol Lung Cell Mol Physiol (321(1), pp. L29-L41). United States.
    6. Sturrock A, Zimmerman E, Helms M, Liou TG, Paine R 3rd (2021). Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19. Physiol Rep (9(9), pp. e14854). United States.
    7. Moughames E, Woo H, Galiatsatos P, Romero-Rivero K, Raju S, Tejwani V, Hoffman EA, Comellas AP, Ortega VE, Parekh T, Krishnan JA, Drummond MB, Couper D, Buhr RG, Paine R, Kaufman JD, Paulin LM, Putcha N, Hansel NN (2021). Disparities in access to food and chronic obstructive pulmonary disease (COPD)-related outcomes: a cross-sectional analysis. BMC Pulm Med (21(1), p. 139). England.
    8. Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE, ONeal WK, Gillenwater LA, Lynch DA, Hoffman EA, Newell JD Jr, Comellas AP, Castaldi PJ, Miller BE, Pouwels SD, Hacken NHTT, Bischoff R, Klont F, Woodruff PG, Paine R, Barr RG, Hoidal J, Doerschuk CM, Charbonnier JP, Sung R, Locantore N, Yonchuk JG, Jacobson S, Tal-Singer R, Merrill D, Bowler RP (2021). Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. Respir Res (22(1), p. 127). England.
    9. Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ, Barr RG, Bleecker ER, Bowler RP, Comellas AP, Cooper CB, Couper DJ, Criner GJ, Curtis JL, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Krishnan JA, Martinez FJ, McDonald MN, Meyers DA, Paine R 3rd, Peters SP, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Levy BD, Li X, Moore WC, Wenzel SE, Zein J, NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study SPIROMICS, NHLBI Trans-Omics for Precision Medicine TOPMed Consortium, Langelier C, Woodruff PG, Lappalainen T, Christenson SA (2021). Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Med (13(1), p. 66). England.
    10. Beesley SJ, Sorensen J, Walkey AJ, Tonna JE, Lanspa MJ, Hirshberg E, Grissom CK, Horne BD, Burk R, Abraham TP, Paine R, Brown SM (2022). Long-Term Implications of Abnormal Left Ventricular Strain During Sepsis. Crit Care Med (49(4), pp. e444-e453). United States.
    11. Turnier L, Eakin M, Woo H, Dransfield M, Parekh T, Krishnan JA, Kanner R, Cooper CB, Woodruff PG, Wise R, Han MK, Romero K, Paulin LM, Peters S, Drummond B, Bleecker ER, Bowler R, Comellas AP, Couper D, Paine R, Martinez F, Barr G, Putcha N, Hansel NN (2021). The influence of social support on COPD outcomes mediated by depression. PLoS One (16(3), pp. e0245478). United States.
    12. Li F, Choi J, Zou C, Newell JD Jr, Comellas AP, Lee CH, Ko H, Barr RG, Bleecker ER, Cooper CB, Abtin F, Barjaktarevic I, Couper D, Han M, Hansel NN, Kanner RE, Paine R 3rd, Kazerooni EA, Martinez FJ, ONeal W, Rennard SI, Smith BM, Woodruff PG, Hoffman EA, Lin CL (2021). Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Sci Rep (11(1), p. 4916). England.
    13. Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, Graham Barr R, Bleecker ER, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper DJ, Doerschuk CM, Dransfield MT, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kaner RJ, Krishnan J, ONeal WK, Ortega VE, Paine R 3rd, Peters SP, Michael Wells J, Woodruff PG, Martinez FJ, Curtis JL, Huffnagle GB, Huang YJ (2021). Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. NPJ Biofilms Microbiomes (7(1), p. 14). United States.
    14. Liou TG, Adler FR, Cahill BC, Cox DR, Cox JE, Grant GJ, Hanson KE, Hartsell SC, Hatton ND, Helms MN, Jensen JL, Kartsonaki C, Li Y, Leung DT, Marvin JE, Middleton EA, Osburn-Staker SM, Packer KA, Shakir SM, Sturrock AB, Tardif KD, Warren KJ, Waddoups LJ, Weaver LJ, Zimmerman E, Paine R 3rd (2020). SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection. Physiol Rep (9(4), pp. e14761). United States.
    15. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM, National Heart Lung and Blood Institute PETAL Clinical Trials Network, Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, OMara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks D (2020). Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA (324(21), pp. 2165-2176). United States.
    16. Kim V, Jeong S, Zhao H, Kesimer M, Boucher RC, Wells JM, Christenson SA, Han MK, Dransfield M, Paine R 3rd, Cooper CB, Barjaktarevic I, Bowler R, Curtis JL, Kaner RJ, OBeirne SL, ONeal WK, Rennard SI, Martinez FJ, Woodruff PG (2020). Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. Sci Rep (10(1), p. 20133). England.